India's private equity firm ChrysCapital has completed the acquisition of a controlling 70.68% stake in Novartis India Ltd (NIL) from Swiss pharmaceutical major Novartis AG, marking its first majority-controlled investment in the country's pharmaceutical sector.
The acquisition brings the BSE-listed pharmaceutical company under private equity ownership, with ChrysCapital aiming to build a leading branded generics platform focused on the Indian market.